- In April 2025, AstraZeneca announced that its experimental oral PCSK9 inhibitor, AZD0780, achieved a 50.7% reduction in LDL cholesterol over 12 weeks when added to statin therapy. This positions it as a strong competitor to existing injectable PCSK9 inhibitors, offering the advantage of oral administration without the need for fasting
- In April 2025 that its single-dose gene-editing therapy, VERVE-101, achieved an average 59% reduction in LDL cholesterol among high-dose recipients in a Phase 1 trial. The therapy, utilizing CRISPR-based base-editing, offers a potentially lifelong solution for patients with genetically elevated LDL-C
- In April 2025, Verve Therapeutics' stock surged by 12.27% in pre-market trading, driven by the company's announcement of promising trial results for its cholesterol drug, VERVE-102
- In Febuary 2025, Despite previous approvals, inclisiran, a small interfering RNA therapy targeting PCSK9, was not included in the American Association of Clinical Endocrinology's 2025 guidelines for dyslipidemia management. The decision was based on limited evidence regarding its impact on cardiovascular outcomes
- In December 2024, LIB Therapeutics submitted a Biologics License Application to the FDA for lerodalcibep, a next-generation PCSK9 inhibitor designed for once-monthly administration. The therapy aims to address limitations of existing treatments by offering a more convenient dosing schedule and improved stability
